We are live on ! Find out more
ENSC icon

Ensysce Biosciences
ENSC

16 hedge funds and large institutions have $3.41M invested in Ensysce Biosciences in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

7% more funds holding

Funds holding: 15 → 16 (+1)

0% less ownership

Funds ownership: 0.01% → 0% (-0%)

45% less capital invested

Capital invested by funds: $6.23M → $3.41M (-$2.82M)

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
2
Closed
3
Calls
$148K
Puts
–
Net Calls
+$148K
Net Calls Change
-$77K

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$56K
2
Renaissance Technologies
Renaissance Technologies
New York
+$53.2K
3
TSS
Two Sigma Securities
New York
+$19.6K
4
PIA
Powell Investment Advisors
Florida
+$14K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$11.2K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$1.34M
2
VF
Virtu Financial
New York
-$28K
3
CAM
Cresset Asset Management
Illinois
-$13K
4
ECM
Evergreen Capital Management
Washington
-$13K
5
TRCT
Tower Research Capital (TRC)
New York
-$5.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
HVCM
1
HG Vora Capital Management
New York
$2.14M – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$309K +$53.2K +19 +24%
BlackRock
3
BlackRock
New York
$203K – – –
Stifel Financial
4
Stifel Financial
Missouri
$188K – – –
AFM
5
Anson Funds Management
Texas
$131K -$1.34M -479 -92%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$110K +$11.2K +4 +13%
Vanguard Group
7
Vanguard Group
Pennsylvania
$106K – – –
Citigroup
8
Citigroup
New York
$62K +$56K +20 New
PIA
9
Powell Investment Advisors
Florida
$61K +$14K +5 +36%
State Street
10
State Street
Massachusetts
$31K – – –
TSS
11
Two Sigma Securities
New York
$21K +$19.6K +7 New
UBS Group
12
UBS Group
Switzerland
$15K +$8.4K +3 +150%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$13K +$11.2K +4 New
SG
14
StoneX Group
New York
$10.3K +$8.4K +3 New
WAM
15
Wolverine Asset Management
Illinois
$4K – – –
TRCT
16
Tower Research Capital (TRC)
New York
$3K -$5.6K -2 -67%
VF
17
Virtu Financial
New York
– -$28K -7 Closed
CAM
18
Cresset Asset Management
Illinois
– -$13K -3 Closed
ECM
19
Evergreen Capital Management
Washington
– -$13K -3 Closed

ENSC Hedge Fund Activity: Q2 2022 in Review

16 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q2 2022, worth a combined $3.41M — down 45% from $6.23M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ENSC positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Citigroup, opening a new position worth an estimated $56K. The largest seller was Anson Funds Management, cutting an estimated $1.34M.

  • 16 institutional investors held Ensysce Biosciences (ENSC) as of Q2 2022, up from 15 in Q1 2022.
  • Funds reported $3.41M of Ensysce Biosciences stock for Q2 2022, down 45% quarter-over-quarter.
  • 4 funds opened new Ensysce Biosciences positions in Q2 2022 and 3 closed out, a net change of +1 holder.
  • The largest Ensysce Biosciences buyer in Q2 2022 was Citigroup, an estimated $56K added.
  • The largest Ensysce Biosciences seller in Q2 2022 was Anson Funds Management, an estimated $1.34M sold.

Based on aggregated 13F filings for Q2 2022.